Table 2.

MIC₅₀ and MIC₉₀ values (mg/L), and EUCAST/CLSI susceptibility profiles based on data from the AWARE Surveillance Program (2012–2017 combined)

	Staphylococcus aureus		Streptococcus pneumoniae	Haemophilus influenzae
	All S. aureus	MRSA
Ceftaroline
Number of isolates	54,479	31,922	11,995	2973
MIC50	0.5	0.5	0.008	≤ 0.015
MIC90	1	1	0.12	0.03
EUCAST
%S	94.1	90	98.8	94.8
%I	N/A	N/A	N/A	N/A
%R	5.9	10	1.2	5.2
CLSI
%S	94.1	90	91.5	99.8
%I	N/A	N/A	6.1	N/A
%R	5.9	10	2.4	0.2
Ceftriaxone
MIC50	32	> 32	0.03	< 0.03
MIC90	> 32	> 32	1	< 0.03
EUCAST
%S	N/A	N/A	81.4	98.3
%I	N/A	N/A	17.4	N/A
%R	N/A	N/A	8.5	1.7
CLSI
%S	N/A	N/A	81.4	100.0
%I	N/A	N/A	10.1	N/A
%R	N/A	N/A	8.5	0.0
Levofloxacin
MIC50	0.5	4	1	0.015
MIC90	> 4	> 4	1	0.03
EUCAST
%S	57.6	32.4	98.7	96.8
%I	N/A	N/A	N/A	N/A
%R	42.4	67.6	1.3	3.2
CLSI
%S	57.6	32.4	98.7	99.2
%I	0.4	0.5	0.1	N/A
%R	42.0	67.1	1.2	0.8

AWARE Assessing Worldwide Antimicrobial Resistance Evaluation, CLSI Clinical and Laboratory Standards Institute, EUCAST European Committee on Antimicrobial Susceptibility Testing, I intermediate, MIC minimum inhibitory concentration, MIC₅₀ MIC values required to inhibit 50%, MIC₉₀ MIC values required to inhibit 90%, MRSA methicillin-resistant S. aureus, N/A not applicable, R resistant, S susceptible